Julphar and the American College of Cardiology Team up for CVDs Awareness

November 7th, 2013 – Julphar (Gulf Pharmaceutical Industries), the UAE leading pharmaceutical company in the MENA region, today announced an exclusive partnership with the American College of Cardiology (ACC), to provide education programs for health care professionals for cardiovascular diseases (CVDs) in the region.

Julphar and the ACC have pledged funds and expertise to address the growing issue of heart diseases in the region through bespoke education programs for health care professionals. The four-year long initiative will involve education seminars, a series of workshops and an annual symposium.

“This partnership between Julphar and ACC, to provide state of the art continuing medical education, to physicians in the UAE, is in line with the mission and vision of the Emirates cardiac society”, said DrWaelAlmahmeed, board member of the ECS and president of the UAE ACC chapter.

Lauding the agreement, Dr. AlyMousa, Senior Sales & Marketing Director of Julphar, said: “This is a major initiative that will definitely boost efforts undertaken by local governments to address the CVDs issue in the UAE and the region. As a healthcare leader in the region committed to improving life and health of the community, we are determined to meet, if not exceed, the goals of this agreement, and we call upon all concerned parties to join hands with us for the good of our communities”.

American College of Cardiology President Dr. John G. Harold, MACC said, “This agreement will give the ACC the opportunity to bring our expertise as leaders in cardiovascular education to the Middle East. We are excited that Julphar’s sponsorship will allow us to bring tailored educational programs to healthcare professionals in the fight against cardiovascular diseases.”

“The ME region is notorious for lifestyle diseases that lead to cardiovascular issues”as addressed by DrEmadALy, JULPHAR Medical Director, and “scores one of the highest rates of CVDs in the world. A recent study conducted by the Emirates Cardiac Society on four thousand people in the UAE, found that 75 % among them have at least one CVD risk factor. The findingssounded strong alarm that 75 percentof the population between 40 and 45 years might be affected by CVDs which are already responsible for 25 percentof deaths every year in the country”.

“As a leading healthcare company in the MENA region, Julphar is keen to join forces with local and international partners to address health issues endemic in the region. Experts from the company are also frequent speakers at local and international health events.Earlier this month, experts from Julphar and others from Iraq & Netherlands were key speakers at theannualJULPHAR cardiovascularconference (JULPHAR CARDIO VI) in Kuala Lumpur addressing the problem of CVD in the ME and the latest guidelines and researchers to reduce CVD burden”.

Julphar is one of the first and the largest local producer of medicines in the MENA region, producing billions of tablets annually”.